Pharmacy News Article

CEDAR KNOLLS, N.J.(BUSINESS WIRE) Emisphere Technologies, Inc. (OTC BB: EMIS), a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen Technology, today announced that President and Chief Executive Officer, Michael V. Novinski, will present a corporate overview at the 13^th Annual Biotech & Specialty Pharma Investment Conference, sponsored by the New York Society of Securities Analysts, at 11:30 AM on December 1, 2009. The conference is being held at the New York Society of Security Analysts, 1177 Avenue of the Americas, New York, NY.

For further information about this conference, please contact Derly Vargas at 646-871-3405 or dvargas@nyssa.org.

About Emisphere Technologies, Inc.

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: www.emisphere.com.

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 (file no. 000-17758) filed on March 16, 2009 and as amended on Form 10-K/A as filed on April 30, 2009, and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2009, and as amended on Form 10-Q/A as filed on October 21, 2009.

Emisphere Technologies, Inc.
Daria Palestina, 973-532-8002
Director Communications
dpalestina@emisphere.com
or
Investors:
Rx Communications Group:
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

Source: Emisphere Technologies, Inc.